Shares of Insulet (NASDAQ:PODD) surged 10.89% in after-hours trading on Thursday following the release of its impressive first-quarter 2025 financial results, which exceeded analyst expectations and prompted the company to raise its full-year revenue guidance.

The medical device company, known for its Omnipod insulin delivery system, reported adjusted earnings per share of $1.02, significantly outperforming the analyst consensus estimate of $0.80. This represents a 27.5% beat and a 39.73% increase from the same period last year. Insulet's quarterly revenue also impressed, coming in at $569 million, surpassing the expected $543.40 million and marking a 28.82% year-over-year growth.

The strong performance was primarily driven by robust demand for Insulet's Omnipod insulin pumps, which generated sales of $554.1 million in the first quarter. The company's Omnipod 5 device, the first system to receive clearance for managing both type 1 and type 2 diabetes, has been particularly well-received in the market. In light of these results, Insulet has raised its full-year revenue growth forecast to 19-22%, up from the previous projection of 16-20%. The company also provided an optimistic outlook for the second quarter, anticipating total revenue growth of 23-26%.

This performance comes at a crucial time for Insulet, as it addresses investor concerns about potential impacts on insulin pump sales due to the increasing demand for new diabetes and weight-loss drugs. The strong results and raised guidance suggest that Insulet's innovative products continue to find a robust market despite evolving treatment landscapes in diabetes care.